Rheomuco, to understand COPD more effectively and validate treatments under development

Rheomuco serves to quantify and objectify the viscoelasticity of sputum to acquire further knowledge on COPD, understand certain mechanisms of this disease, and identify and validate new treatments.

COPD, Chronic Obstructive Pulmonary Disease, is a chronic inflammatory disease affecting the lungs.

People with COPD find it harder to breathe due to the thickening of the bronchi and bronchioles as the smooth muscles deteriorate and more mucus is secreted.

Rheomuco, an instrument specifically designed to measure the viscoelasticity of sputum, was the subject of a clinical trial “Assessment of Rheological Parameters of Human Sputum” [Rheomuco, NCT02682290] at Grenoble-Alpes University Hospital. The initial results were presented in 2018 at the international conference of the European Respiratory Society.
The trial made it possible to distinguish between COPD patients, healthy volunteers and asthma patients, and to measure the impact of a treatment on the viscoelasticity of sputum.

An in vitro diagnostic medical device (IVDMD) is being explored for early diagnosis and monitoring of COPD patients.